BioAtla (BCAB) Stock Highlights

1.48 | -1.33%

2024-11-21 05:52:01

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.

Statistics

Range Today

1.43 1.53

Volume Today 635.7K

Range 1 Year

1.14 4.02

Volume 1 Year 209.36M

Range 3 Year

1.14 27.91

Volume 3 Year 510.83M

Range 10 Year

1.14 76.63

Volume 10 Year 569.16M

Highlights

Market Capitalization 101.51M (small)

Floating Shares 37.47M

Current Price 1.48

Price To Earnings -1.09

Price To Book 1.43

Earnings Per Share -2.06

Payout Ratio 0%

Performance

Latest -1.33%

1 Month -22.92%

3 Months -21.28%

6 Months -48.07%

1 Year -10.84%

3 Years -94.62%

5 Years -95.16%

10 Years -95.16%

Benchmarks

Market Capitalization

244 / 368

Gross Profits

223 / 278

Total Revenue

0 / 300

Total Rank

238 / 368

Free Cashflow

228 / 352

Performance 5 years

310 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.